Meta-analysis examines risks of bleeding, breast cancer, breast cancer recurrence, breast enlargement
WEDNESDAY, Nov. 4, 2015 (HealthDay News) — There is no evidence to support antidepressant medication cessation in patients undergoing plastic surgery, according to a meta-analysis published in the November issue of Plastic & Reconstructive Surgery.
Isabel Teo, M.B.Ch.B., from Ninewells Hospital in Dundee, and Christopher Tam Song, M.B.Ch.B., from the University of Edinburgh, both in the United Kingdom, conducted a comprehensive literature review to examine the risks of patient antidepressant treatment in relation to plastic surgery. Twenty-six articles were included in the analysis and classified into five groups: risk of bleeding, risk of breast cancer, risk of breast cancer recurrence, breast enlargement, and miscellaneous.
The researchers found that, based on the evidence, there was no indication to support cessation of antidepressant use in patients before plastic surgery. The numbers needed to harm were low and withdrawal had implications that were potentially detrimental to postoperative management. There was no increased risk of breast cancer or recurrence overall, but patients on concurrent tamoxifen and paroxetine treatment may be at increased risk.
“Depression itself may be associated with poor surgical outcomes and may have played a confounding role in results of the studies,” the authors write. “Unfortunately, more data are mandatory to warrant specific recommendations.”
Full Text
Copyright © 2015 HealthDay. All rights reserved.
